Novartis Oncology is conducting a clinical research study to see if an investigational drug called patupilone is an effective and safe treatment for women with recurrent epithelial ovarian, primary fallopian, or primary peritoneal cancer. Novartis is seeking patients with these three types of cancer. The patient must have been previously treated with chemotherapy and the cancer must have come back in less than six months after treatment.

If you or a family member or a friend has been diagnosed with any of these types of cancer and the cancer has come back within six months after chemotherapy treatment, you may be eligible to participate in this clinical trial. Please click on the link below to take a brief screening questionnaire to see if you may be eligible.

to see if you qualify for the study.